Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
An anaplastic oligodendroglioma that has material basis in IDH gene family mutation and combined whole-arm losses of 1p and 19q (1p/19q codeletion).
Biomarker and diagnostic research for IDH-mutant and 1p/19q-codeleted oligodendroglioma has been reported in the published literature.
No clinical trials have been registered for IDH-mutant and 1p/19q-codeleted oligodendroglioma.
5 publications have been identified in PubMed for IDH-mutant and 1p/19q-codeleted oligodendroglioma. Research spans Diagnostic / Biomarker (60%), Review / Meta-Analysis (20%), and Epidemiology / Natural History (20%).
Ozono I (2026). [PMID: 41189118](https://pubmed.ncbi.nlm.nih.gov/41189118/). *Japanese journal of clinical oncology*. [Diagnostic / Biomarker]
Hinz FE (2025). [PMID: 41299137](https://pubmed.ncbi.nlm.nih.gov/41299137/). *Acta neuropathologica*. [Diagnostic / Biomarker]
Bauchet L (2025). [PMID: 39710298](https://pubmed.ncbi.nlm.nih.gov/39710298/). *Neuro-Chirurgie*. [Epidemiology / Natural History]
Bao J (2025). [PMID: 40448901](https://pubmed.ncbi.nlm.nih.gov/40448901/). *Discover oncology*. [Review / Meta-Analysis]
Yamashita K (2025). [PMID: 39831960](https://pubmed.ncbi.nlm.nih.gov/39831960/). *Neuroradiology*. [Diagnostic / Biomarker]
Data assembled from 2 of 12 sources · Last updated Sep 19, 2026, 6:47 AM UTC
Common questions about IDH-mutant and 1p/19q-codeleted oligodendroglioma